肝郁证模型大鼠蓝斑蛋白质组差异表达研究
|
摘要
研究背景：
辨证论治是中医学的特色和精髓,突出了个性化的中医思路。“证”是中医学的一个特有概念,是对疾病过程中所处一定阶段的病位、病因、病性以及病势所作的病理性概括。证是机体内因和环境外因综合作用的机体反应状态,随着病程的发展而不断发生变化。证是对疾病当前本质所作的结论。因此,证的研究是中医学现代化研究的核心内容。
近年来,随着基因组测序工作的完成,人们研究的重点已经从基因转移到蛋白质功能方面,蛋白质在疾病的发生发展中承担着重要的角色,这使得蛋白质组学在人类疾病的研究中有着极为重要的价值。蛋白质组学是一门在整体水平上高通量、大规模地研究蛋白质组成及其动态变化的活动规律,从而得到疾病、生理生化过程中的整体情况的新兴学科。蛋白质组学从一个机体或一个组织,一个细胞等不同层次“整体”的蛋白质活动的角度,来揭示和阐明证候形成和发展的基本规律。其理论和技术特点以及其整体、动态性的核心思想,与中医学的“整体观”和“辨证观”等理论体系有很大的相似性,这种研究思路与中医整体观和中药多靶点整合调节的特点不谋而合,具有明显的中医特色。
肝郁证是由于肝的疏泄功能异常,疏泄不及而致气机郁滞所引起的情绪不宁、胸胁闷胀或易怒善哭为特征的一类临床病证,常见于临床多种疾病。临床流行病学调查显示,肝脏病证在五脏病证中占总体病证的40%,而肝郁证又是肝病证候的核心,也是中医肝病发病学的重要环节,因此肝郁证的本质研究一直是中西医结合领域研究的热点。近年来对肝郁证本质的研究颇多,已初步证实肝郁证具有现代病理生理学基础,并部分地阐释了中医理论的科学性,取得了阶段性成果：认为肝郁证和应激密切相关,并涉及机体神经、内分泌、循环、消化、免疫等多系统多器官的病理改变。近年来对应激相关的下丘脑-垂体-肾上腺皮质系统(Hypothalamic Pituitary Gonadal Axis,HPA)和蓝斑-交感-肾上腺髓质系统(locus coeruleus-sympathetic-adrenal medulla system,LC-NE)研究较多,我们课题组之前的研究表明肝郁证可引起蓝斑中酪氨酸羟化酶(tyrosine hydroxylasw,TH)、c-fos表达的上调,进一步阐明了蓝斑和肝郁证的相关性。
肝郁证是中医经典病证,其方证研究也一直是其本质研究的一个重要方面。中医证候研究具有“以方测证,方证互参”的特点。一方面通过辨证的结果来确立相应的治法方药,一方面又根据方药的组成和功效来推测疾病的病机和症状。理论上讲,每一个方剂都有自己使用的病证,只有当其功效与疾病的病机相应时,方剂的效用才达到最佳。通过这一特征,我们可以通过建立预设的动物疾病模型,然后给予预设的方药,选择和疾病证候相关的差异指标,通过对用药后动物的观察和研究,确认该模型是否为预设的疾病模型。同时,在确定模型的情况下,选用特定方剂,通过观察差异指标,可以证实该方剂是否是治疗此病证的有效方剂。
因此,本课题以蓝斑为切入点,通过蛋白质组学进行差异蛋白鉴定,并从中选取鉴定出的已知蛋白羧肽酶A抑制剂(Latexin/endogenous carboxypeptidase inhibitor,ECI),沉默信息调节基因2(silent information regulator2,Sirt2),转体基因蛋白(Transthyretin,TTR),并通过逍遥散进行反证,同时选用了西药阳性对照盐酸氟西汀(氟西汀是临床经典抗抑郁药,可有效改善闷闷不乐,兴趣减退等肝郁证症状),希望为蓝斑和肝郁证的相关性提供更进一步的证据,并对进一步研究肝郁证的本质打下一定的基础。
研究目的：
采用孤养加慢性不可预知温和刺激(chronic unexpected mild stress,CUMS)制备肝郁证大鼠模型,观察肝郁证大鼠在一般状态、行为学及从蛋白质的角度,对肝郁证模型大鼠蓝斑组织蛋白质组的差异表达进行比较分析并进行验证,从动物模型的角度找到肝郁证相关的蛋白质组群,从而为建立证候的微观辨证指标体系奠定基础,也为从临床疾病的角度对肝郁证相关蛋白质组的全面研究提供技术和理论支持。并通过比较逍遥散组和氟西汀组与模型组大鼠之间的蛋白表达差异,探讨逍遥散对肝郁证的作用机理,并以方测证,方证互参,为肝郁证本质的阐述提供客观依据。
研究方法：
本研究在肝郁证理论指导下建立孤养加CUMS肝郁证大鼠模型。并运用蛋白质组学研究中常用的二维凝胶电泳(two-dimensional gel eleetrophoresis,2-DE)分离方法,结合基质辅助激光解吸电飞行时间质谱技术(matrix assisted laser desorption time-of-flight mass spectrometry,MALDI-OF-MS),分析模型组大鼠蓝斑组织的蛋白质组和正常组大鼠之间的表达差异。
1、孤养加CUMS肝郁证大鼠模型的建立
分两次造模,第一次用于差异蛋白的检测和鉴定,第二次用于蛋白功能的验证。参照相关文献报道,从慢性心理应激的角度出发,将18只雄性SD大鼠随机分为正常组,模型组,逍遥散组,每组6只(第二次为72只,分组增加盐酸氟西汀组,每组18只)。除正常组外,其他各组大鼠均单笼饲养,并给予慢性不可预知温和刺激,每天2次,持续3周。逍遥散组在模型制备的基础上加用逍遥散干预,氟西汀组加用氟西汀干预,正常组不给任何干预,群养。
2、蛋白质样本的提取和样本混合
以液氮研磨蓝斑组织,低温裂解蓝斑细胞,提取蓝斑组织的蛋白质样本。采用BSA法对蛋白质样本进行定量。对组内的蓝斑组织,按等质量进行样本混合。
3、蓝斑组织的2-DE分离
在常规蛋白质组2-DE分离技术基础上,引入“盐桥”和低电压除盐方法,进一步优化蓝斑组织蛋白质组2-DE分离技术。对同类混合样本以组间配对的形式,同时进行2-DE分离,并重复3次。
4、凝胶染色和图像分析
对2-DE分离所获得的凝胶,采用新型的胶体考染技术,不仅可以提高凝胶染色的灵敏度,而且还能减少对后期质谱检测的干扰。凝胶经过染色和脱水后,用光密度透射扫描仪扫描而形成图像。用PDQuest7.0软件分析凝胶图像,获取每个蛋白质的表达量、等电点、分子量等信息。并将组间表达量相差2倍以上的蛋白质斑点设定为差异表达蛋白质,由软件自动生成分析结果,再加以人工验证。
5、差异表达蛋白质斑点质谱鉴定和数据库确认
用MALDI-TOF-MS对分析所获得的差异蛋白质斑点进行肽质量指纹(peptide mass figerint,PMF)的检测。首先,在凝胶上切取差异表达蛋白质斑点,再经水洗、脱色、还原与烷基化、酶解、萃取、点样和质谱分析等步骤获取每个蛋白质斑点的PMF。然后,利用Masoct软件搜索各大生物和蛋白质相关数据库,寻找与目的PMF相匹配的蛋白质,并查询该蛋白质的相关信息。
6、运用化学发光免疫法检测各组大鼠血清中三碘甲状腺氨酸(T3)、甲状腺素(T4)和促甲状腺激素(TSH)含量。
7、运用苏木精-伊红(hematoxylinandeosinstain,HE)染色,观察大鼠蓝斑的形态学变化。
8、用免疫组化法(immunology and histology chemistry,IHC)检测蓝斑中Laxetin、 Sirt2和TTR的表达变化。用Imageproplus6.0软件进行分析。
9、运用免疫印迹法(weastern blot, WB)检测Laxeti、Sirt2和TTR在蓝斑中的表达变化
10、用实时荧光定量聚合酶链反应(real time-polymerase chain reaction,RT-PCR)技术检测Laxetin、Sirt2和TTR中mRNA在蓝斑中的表达情况。
11、所有数据用spss13.0软件进行分析统计。
实验结果均用平均值±标准差(X±S)表示,采用SPSS13.0软件统计包处理。体重的变化采用重复测量数据的方差分析,其余指标多样本均数比较采用单因素方差分析,方差齐性,多重比较采用LSD法检验,若方差不齐,采用Welch分析,多重比较采用Tamhane's T2法检验,以P<0.05作为具有显著性差异。
结果：
1、成功制备了孤养加CUMS肝郁证大鼠模型。造模3周后,从一般情况来看,模型组大鼠开始表现为躁动,易激惹,随后逐渐安静,表现为倦怠少动,喜欢贴壁,反应迟钝,食欲减退,伴有毛色暗淡无光泽,松散,大便稀软等肝郁证表现。逍遥散组和氟西汀组上述反应明显低于模型组,且两药物组间无显著性差异(P>0.05)。而正常对照组未见异常行为状态。各组间体重增长存在显著差异(P=0.017),模型组生长较缓慢,逍遥散组和氟西汀组服药后体重增长缓慢的情况得到改善,且与模型组有显著差异(P=0.000)。糖水消耗实验提示各组间糖水偏好存在显著性差异((P=0.000),模型组的糖水偏好度明显小于其他组。旷场实验发现模型组大鼠的直立次数和爬格数均显著低于正常组(P=0.000),逍遥散组和氟西汀组则显著优于模型组,但和正常组比较仍有差异(P=0.000)。说明孤养加CUMS确能造成大鼠的肝郁证,能有效的模拟临床中肝郁证兴趣丧失、快感缺乏等症状。
2、获得了高质量的蓝斑组织蛋白质组2-DE凝胶电泳图像。经2-DE分离和对凝胶图像的软件分析,发现了21个蛋白质斑点在三组间(正常组,模型组,逍遥散组)有差异表达。
3、差异蛋白质斑点的质谱检测：出峰率达100%,经过对PMF的分析和数据库检测,确定肝郁证模型大鼠中表达具有显著性差异的蓝斑组织蛋白质17个。
4、血清中T3和T4含量在模型组中最高,逍遥散组和氟西汀组次之,正常组中含量最低(P=0.000),TSH含量则在各组大鼠间的差异均无统计学意义(P=0.740)。
5、HE染色显示各组大鼠蓝斑无明显的形态学改变。
6、IHC检测发现模型组蓝斑Laxetin、Sirt2和TTR的阳性神经元数目均小于正常组,染色强度减弱,平均光密度值也低于正常组。逍遥散组和氟西汀组则可以改善这种情况。
7、WB检测模型组Laxetin、Sirt2和TTR的表达量均低于正常组,逍遥散组和氟西汀组则较模型组表达增加。
8、运用RT-PCR技术检测Laxetin、Sirt2和TTR的mRNA在LC中的表达,发现与正常组比较,模型组表达量均减少,逍遥散组和氟西汀组则较模型组升高。
结论：
对肝郁证孤养加CUMS动物模型进行了蓝斑的蛋白质组的研究,通过分析模型大鼠蓝斑组织蛋白质组的差异表达,获得和肝郁证动物模型密切相关的差异蛋白21个,其中17个可以获得数据库的匹配信息,确定蛋白质名称。我们在这17个蛋白质中选取了Laxetin、Sirt2和TTR这三种蛋白进行进一步的验证。这3种蛋白双向电泳结果提示Latexin和TTR在模型组表达下降,Sirt2在模型组表达上升。我们又采用IHC、WB、RT-PCR三种实验技术同时证明在肝郁证中Laxetin、Sirt2和TTR蛋白表达下降,且逍遥散和氟西汀可以改善这一情况,提示这三种蛋白参与了肝郁证的发病过程,且逍遥散和氟西汀均对其有效,疗效无显著差异。同时提示双向电泳鉴定出的蛋白表达情况只是前期的一种提示,并不一定是100%匹配的,这样我们后面采用三种不同技术验证3种蛋白的表达增加了结果的可信度。该结果为进一步研究肝郁证的分子机制提供了理论基础,也使肝郁证的实质研究有了进一步的发展。但关于这三种蛋白质和肝郁证之间的直接关系尚未明确验证和阐释,有待进一步研究。
Research background:
Syndrome differentiation and treatment are the characteristic and the essence of the Traditional Chinese Medicine.It emphasizes the personalized thinking of TCM."Syndrome" is a unique concept of TCM, it refers to the pathological generalization of the location, etiology, nature and the progression of diseases.Syndrome is a state of our body caused by internal and external factors, it is changing with the development of disease.Syndrome is conclusion about the current essence of the disease.So, the study of nature of disease is the central content of the modernization of TCM.
In recent years,with the draft of the human genome has been completed,the focus of research is moving beyond genomics to proteomics.Protein has been playing an increasingly important role in the development of disease.This makes Proteomics quite valuable in the study of human diseases.As a new subject,proteins research the composition and of protein and its dynamic variety from the whole to grasp the whole situation of the physiological and biochemical process in the disease.Proteomics is an new research field that focuses on a whole set of proteins in a cell or a tissue of an organism.lt explains and clarifies the basic rules of the formation and development of Syndrome.It has overall and dynamic characters,and this is its core idea and it has its own theory and technology traits.From these points,Proteomics is very similar to the TCM theoretical system of the overall concept and individualization.This kind of research idea coincides with the characters of TCM.So this idea has obvious characters of Chinese medicine science.
Liver depression syndrome is one of the common diseases which is caused by the dysfunction of liver and with the characters of depression,choking sensation in chest and irritable.Clinical epidemiology survey showed that liver diseases in the the viscera account for40%of the overall disease.Liver depression syndrome is the core syndrome of the liver disease and play an important role in the pathogenesis of the liver disease.Therefore,the nature of liver depression syndrome is always the hot topic in the area of Combine traditional Chinese and western medicine.There have been more and more researches about nature of the liver depression syndrome in recent years.Some preliminary research suggests that liver depression syndrome has modern pathophysiology basis and partly explain the scientificalness of TCM theory.We have achieved some stage achievements.Some researches indicate that Liver depression syndrome is likely to result from regulating function disorder of high nervous centre induced by negative psychic stress in which pathological changes of multi-system including nerve,endocrine,circulation,digestion,immunity,feeling and motion etc are involved.In recent years,the study of HPA and LC-NE axis has been developed rapidly.We seminar previously discovered liver depression syndrome can cause the up regulation of TH and c-fos in LC.This proved the relationship between LC and liver depression syndrome.
Liver depression syndrome is one of the classic syndromes of liver disease of TCM.The research about its prescription and syndrome is always the most important aspect.The TCM Syndrome research has two feartures.One is to establish corresponding treatment through the result of syndrome differentiation,and the other is to infer the mechanism and symptoms of the disease from the composition and effect of the prescription.In theory,every prescription has its own applicable syndromes and only when the effect of prescription is appropriate for the mechanism of the disease,effect of the prescription can achieve optimal.Through this characteristic,we can establish the pre-determined animal disease models and then interfere them with the pre-determined prescription.After that, we select some abnormal indicators related to the disease and reaearch the animal models that are interfered to estimate whether the disease models are our pre-determined or not.At the same time,in the circumstance that the validation of the animal disease model is good,we observe and study some abnormal indicators and make sure the prescription we select is effect for this disease.
Therefore, we hope to provide further evidence for the correlation of liver depression syndrome and LC and lay a solid foundation for the further study of the nature of liver depression syndrome by research into LC according to the methods of proteomics.Meanwhile, we selected some proteins and used xiaoyaosan to disprove it.Fluoxtine was selected as the positive-controlled medicine for its classic anti-depression effect.
Objective:
To set up the rat model of liver depression syndrome using the method of separation and chronic unpredictable mild stress to find the differentia of general condition and behaviorististics and from the point of proteomics,find the differentially expressed protein in the rat model of liver depressiom.And select the protein which we are interested in to verify.To discover the proteins related to liver depression syndrome from the reaearch of rat model and lay the foundation for the microcosmic differentiation indicatoers system of syndrome.At the same time, to provide technical and theoretical support for the comprehensive investigation on the related proteins from the point of clinical diseases.To explain the essence of liver depression syndrome and to study the clinical effect and mechanism of xiaoyaosan treating the it by comparing the differential expression proteins in the group of xiaoyaosan,fluoxetine and the model group.
Methods:
This study established the rat model of liver depression syndrome by the method of separation and chronic unpredictable mild stress(CUMS).We used two dimensional gel electrophoresis(2-DE)to sepatate the LC proteins,combining with matrix assisted laser desorption time-of-flight mass spectrometry(MALDI-OF-MS),to analyse the differential expression proteins in rat LC between the model group and the normal group.
1. Established the rat model of liver depression syndrome by the method of separation and CUMS.
We established two times of the rat model.The first time is for detection and identification to the differential proteins, the second time is for validation.We used the method of separation and CUMS according to the related literature reports. Eighteen female SD rats with SPF level and were into three groups according to a completely random method.Those were normal control group,liver depression syndrome model group,xiaoyaosan group and fluoxetine group.In each group, there were six rats.(in the second time,there were72rats and were randomly divided into four groups.) Except normal group,rats of other groups were feed separately and were induced by a group of CUMS2times every day for three weeks.Xiaoyaosan group was combined with the interferon of xioayaosan on the basis of the model rats and fluoxetine group with fluoxetine intervention.At the same time, the normal group was feed freely and collectively.
2. The extraction of protein sample and sample mix.
Grinded the LC organization using the liqid nitrogen and lysed the LC cells at a low tempreture.We extracted proteins from LC and made protein quantification by the method of BCA.And mixed the LC regnization in the same group according to the weight.
3.2-DE separation of LC.
We introduced the methods of salt brige and low voltage desalination on the basis of conventional separation technology of proteins to future optimize this technology.The samples were pair-matched.We made the2-DE separation for all the groups and repeated for three times.
4. Gel staining and image analysis.
A new kind of colloidal dye technology was used on the gel we obtained from the2-DE separation.On the one hand,this method can improve the sensitivity of gel staining,on the other hand,it can reduce the interference in the later mass-spectrometric detection.After dyeing and dehydration,the gels were scanned by optical density transmission scanners and the images were got. We used the software of PDquest7.0to analyze the images of gels and got the quantity of each protein expression,soelectric point and the molecular weight of proteins and so on.The protein spot whose expression has more than two times difference was defined to differentially-expressed protein,the results were automatically generated by the software and then were verified manually.
5. The mass spectrometry identification and database confirm of differentially expressed protein spots.
To the differentially expressed protein spots which we received,we applied MALDI-TOF-MS to make the detection of peptide mass figerint(PMF).We cut out the protein spots first and then got the PMF of every protein spot by the steps of water-washing, decolorizing, reduction and alkylation, digestion, extraction, sample and mass spectrometry.After these, we searched major biological and protein-related database by the software of Mascot, to find the proteins which are matched with the PMF we have got and know about the related information.
6. CLIA to test T3, T4and TSH levels of serum in different groups.
7. HE stain to observe morphological changes of LC.
8. Immunohistochemical method to detect the expression changes of the protein we choose in LC and analyze the results by Imageproplus6.0software.
9. Western blot method to detect the expression changes of the protein we choose in LC.
10. RT-PCR technology to detect the expression changes of total RNA of the gene we choose in LC.
11. Statistical analysis.
The experimental results are expressed by x±s. SPSS13.0software was applied for it.ANOVA of repeated measures was applied for the weight changes.For the other indicators, the mean comparison of multiple samples used One Way ANOVA to analyse.When the variance was homogeneous, Least-significant difference (LSD) was applied for multiple comparison and when the variance was heteroscedastic, Tamhane's T2was applied for multiple comparison and the value of P≤0.05would mean significant difference.
Results:
1. We made the rat model of liver depression syndrome succeedly.During the3weeks we interfered them by CUMS procedures,the model rats first were easily angery and then displayed the typical appearance such as low activity,slow reaction,reduces food and drink.Rats from xiaoyaosan group and fluoxtein group also showed some above abnormalities,but they were not obvious.There were no difference between the two medicine groups.Rats in normal group lived well.The rats'weight increase was significantly different between groups(P=0.017).It showed rats in model group grow slowest,while rats in xiaoyaosan group and fluoxetine group grow more than them.Fluid consumption test reavealed that the model group lose appetite for sweet water after3weeks.Statistics showed that there were differences between the three groups(P=0.000).The open field test reavealed that the erect times and travelling grids both reduced in model group and had statistical differences(P=0.000),xiaoyaosan group and fluoxetine group were better than it,but still have a gap with the normal group(P=0.000).The results showed that separation and CUMS could eatablish the model of liver depression syndrome succeedly and simulate clinical symptoms of liver depression syndrome such as interest loss and anhedonia.
2.2-DE was used to separate the whole proteins of LC and the ideal2-DE maps were obtained.Tweenty one differential protein spots were checked out in the three groups(normal, model and xiaoyaosan group).
3. We found seventeen differential proteins by the mass spectrometry identification and database confirm of differentially expressed protein spots.
4. T3and T4levels in serum was highest in the model group and lowest in the normal group, the levels in xiaoyaosan group and fluoxetine group were between the two groups (P=0.000).TSH levels of serum in all the groups were not statistically significant (P=0.740).
5. HE staining showed no obvious morphological change of locus coeruleus in all of groups.
6. Expression results of Immunohistochemical detection of LC showed that the number and mean density of Laxetin,Sirt2and TTR positive cells in model group were lower than others(P<0.05).
7. Expression results of Weatern Blot showed that the expression of Laxetin, Sirt2and TTR were all lower than others(P<0.05).
8. The expression of LaxetinmRNA, Sirt2mRNA and TTRmRNA by RT-PCR was observed that all were reduced in model group while xiaoyaosan group and fluoxetine group were higher than it.
Conclusion:
We eatablished the rat model of liver depression syndrome by separation and CUMS and researched the LC proteomics.21differential proteins related to liver depression syndrome were obtained,among them17proteins could be matched with the information in database to determine their names.Then,we selected the proteins of Latexin,Sirt2and TTR from the17proteins to further verified.Among the3proteins,2-DE results suggested that the expression of Latexin and TTR were reduced in model group and Sirt2was up-regulated.Then IHC,WB and RT-PCR technologys were used to prove that the expression of Laxetin,Sirt2and TTR was reduced in liver depression syndrome and xiaoyaosan,fluoxetine could improve this condition. The results revealed the three proteins involved in the process of liver depression syndrome.Xiaoyaosan and fluoxetine play the same role in it and have no differences. This result suggests that the expression of proteins identified by2-DE is just a prompt and is not necessarily a100%exact match.So we used three other methods to further verify the expression of the three proteins to increase the credibility.The results provided theoretical basis for the further research of the molecular mechanisms of liver depression syndrome, and make the essence study of liver depression syndrome have a further development.But the direct relationship between the three proteins and liver depression syndrome has not yet validated and elaborated. This remains to be further research.
辨证论治是中医学的特色和精髓,突出了个性化的中医思路。“证”是中医学的一个特有概念,是对疾病过程中所处一定阶段的病位、病因、病性以及病势所作的病理性概括。证是机体内因和环境外因综合作用的机体反应状态,随着病程的发展而不断发生变化。证是对疾病当前本质所作的结论。因此,证的研究是中医学现代化研究的核心内容。
近年来,随着基因组测序工作的完成,人们研究的重点已经从基因转移到蛋白质功能方面,蛋白质在疾病的发生发展中承担着重要的角色,这使得蛋白质组学在人类疾病的研究中有着极为重要的价值。蛋白质组学是一门在整体水平上高通量、大规模地研究蛋白质组成及其动态变化的活动规律,从而得到疾病、生理生化过程中的整体情况的新兴学科。蛋白质组学从一个机体或一个组织,一个细胞等不同层次“整体”的蛋白质活动的角度,来揭示和阐明证候形成和发展的基本规律。其理论和技术特点以及其整体、动态性的核心思想,与中医学的“整体观”和“辨证观”等理论体系有很大的相似性,这种研究思路与中医整体观和中药多靶点整合调节的特点不谋而合,具有明显的中医特色。
肝郁证是由于肝的疏泄功能异常,疏泄不及而致气机郁滞所引起的情绪不宁、胸胁闷胀或易怒善哭为特征的一类临床病证,常见于临床多种疾病。临床流行病学调查显示,肝脏病证在五脏病证中占总体病证的40%,而肝郁证又是肝病证候的核心,也是中医肝病发病学的重要环节,因此肝郁证的本质研究一直是中西医结合领域研究的热点。近年来对肝郁证本质的研究颇多,已初步证实肝郁证具有现代病理生理学基础,并部分地阐释了中医理论的科学性,取得了阶段性成果：认为肝郁证和应激密切相关,并涉及机体神经、内分泌、循环、消化、免疫等多系统多器官的病理改变。近年来对应激相关的下丘脑-垂体-肾上腺皮质系统(Hypothalamic Pituitary Gonadal Axis,HPA)和蓝斑-交感-肾上腺髓质系统(locus coeruleus-sympathetic-adrenal medulla system,LC-NE)研究较多,我们课题组之前的研究表明肝郁证可引起蓝斑中酪氨酸羟化酶(tyrosine hydroxylasw,TH)、c-fos表达的上调,进一步阐明了蓝斑和肝郁证的相关性。
肝郁证是中医经典病证,其方证研究也一直是其本质研究的一个重要方面。中医证候研究具有“以方测证,方证互参”的特点。一方面通过辨证的结果来确立相应的治法方药,一方面又根据方药的组成和功效来推测疾病的病机和症状。理论上讲,每一个方剂都有自己使用的病证,只有当其功效与疾病的病机相应时,方剂的效用才达到最佳。通过这一特征,我们可以通过建立预设的动物疾病模型,然后给予预设的方药,选择和疾病证候相关的差异指标,通过对用药后动物的观察和研究,确认该模型是否为预设的疾病模型。同时,在确定模型的情况下,选用特定方剂,通过观察差异指标,可以证实该方剂是否是治疗此病证的有效方剂。
因此,本课题以蓝斑为切入点,通过蛋白质组学进行差异蛋白鉴定,并从中选取鉴定出的已知蛋白羧肽酶A抑制剂(Latexin/endogenous carboxypeptidase inhibitor,ECI),沉默信息调节基因2(silent information regulator2,Sirt2),转体基因蛋白(Transthyretin,TTR),并通过逍遥散进行反证,同时选用了西药阳性对照盐酸氟西汀(氟西汀是临床经典抗抑郁药,可有效改善闷闷不乐,兴趣减退等肝郁证症状),希望为蓝斑和肝郁证的相关性提供更进一步的证据,并对进一步研究肝郁证的本质打下一定的基础。
研究目的：
采用孤养加慢性不可预知温和刺激(chronic unexpected mild stress,CUMS)制备肝郁证大鼠模型,观察肝郁证大鼠在一般状态、行为学及从蛋白质的角度,对肝郁证模型大鼠蓝斑组织蛋白质组的差异表达进行比较分析并进行验证,从动物模型的角度找到肝郁证相关的蛋白质组群,从而为建立证候的微观辨证指标体系奠定基础,也为从临床疾病的角度对肝郁证相关蛋白质组的全面研究提供技术和理论支持。并通过比较逍遥散组和氟西汀组与模型组大鼠之间的蛋白表达差异,探讨逍遥散对肝郁证的作用机理,并以方测证,方证互参,为肝郁证本质的阐述提供客观依据。
研究方法：
本研究在肝郁证理论指导下建立孤养加CUMS肝郁证大鼠模型。并运用蛋白质组学研究中常用的二维凝胶电泳(two-dimensional gel eleetrophoresis,2-DE)分离方法,结合基质辅助激光解吸电飞行时间质谱技术(matrix assisted laser desorption time-of-flight mass spectrometry,MALDI-OF-MS),分析模型组大鼠蓝斑组织的蛋白质组和正常组大鼠之间的表达差异。
1、孤养加CUMS肝郁证大鼠模型的建立
分两次造模,第一次用于差异蛋白的检测和鉴定,第二次用于蛋白功能的验证。参照相关文献报道,从慢性心理应激的角度出发,将18只雄性SD大鼠随机分为正常组,模型组,逍遥散组,每组6只(第二次为72只,分组增加盐酸氟西汀组,每组18只)。除正常组外,其他各组大鼠均单笼饲养,并给予慢性不可预知温和刺激,每天2次,持续3周。逍遥散组在模型制备的基础上加用逍遥散干预,氟西汀组加用氟西汀干预,正常组不给任何干预,群养。
2、蛋白质样本的提取和样本混合
以液氮研磨蓝斑组织,低温裂解蓝斑细胞,提取蓝斑组织的蛋白质样本。采用BSA法对蛋白质样本进行定量。对组内的蓝斑组织,按等质量进行样本混合。
3、蓝斑组织的2-DE分离
在常规蛋白质组2-DE分离技术基础上,引入“盐桥”和低电压除盐方法,进一步优化蓝斑组织蛋白质组2-DE分离技术。对同类混合样本以组间配对的形式,同时进行2-DE分离,并重复3次。
4、凝胶染色和图像分析
对2-DE分离所获得的凝胶,采用新型的胶体考染技术,不仅可以提高凝胶染色的灵敏度,而且还能减少对后期质谱检测的干扰。凝胶经过染色和脱水后,用光密度透射扫描仪扫描而形成图像。用PDQuest7.0软件分析凝胶图像,获取每个蛋白质的表达量、等电点、分子量等信息。并将组间表达量相差2倍以上的蛋白质斑点设定为差异表达蛋白质,由软件自动生成分析结果,再加以人工验证。
5、差异表达蛋白质斑点质谱鉴定和数据库确认
用MALDI-TOF-MS对分析所获得的差异蛋白质斑点进行肽质量指纹(peptide mass figerint,PMF)的检测。首先,在凝胶上切取差异表达蛋白质斑点,再经水洗、脱色、还原与烷基化、酶解、萃取、点样和质谱分析等步骤获取每个蛋白质斑点的PMF。然后,利用Masoct软件搜索各大生物和蛋白质相关数据库,寻找与目的PMF相匹配的蛋白质,并查询该蛋白质的相关信息。
6、运用化学发光免疫法检测各组大鼠血清中三碘甲状腺氨酸(T3)、甲状腺素(T4)和促甲状腺激素(TSH)含量。
7、运用苏木精-伊红(hematoxylinandeosinstain,HE)染色,观察大鼠蓝斑的形态学变化。
8、用免疫组化法(immunology and histology chemistry,IHC)检测蓝斑中Laxetin、 Sirt2和TTR的表达变化。用Imageproplus6.0软件进行分析。
9、运用免疫印迹法(weastern blot, WB)检测Laxeti、Sirt2和TTR在蓝斑中的表达变化
10、用实时荧光定量聚合酶链反应(real time-polymerase chain reaction,RT-PCR)技术检测Laxetin、Sirt2和TTR中mRNA在蓝斑中的表达情况。
11、所有数据用spss13.0软件进行分析统计。
实验结果均用平均值±标准差(X±S)表示,采用SPSS13.0软件统计包处理。体重的变化采用重复测量数据的方差分析,其余指标多样本均数比较采用单因素方差分析,方差齐性,多重比较采用LSD法检验,若方差不齐,采用Welch分析,多重比较采用Tamhane's T2法检验,以P<0.05作为具有显著性差异。
结果：
1、成功制备了孤养加CUMS肝郁证大鼠模型。造模3周后,从一般情况来看,模型组大鼠开始表现为躁动,易激惹,随后逐渐安静,表现为倦怠少动,喜欢贴壁,反应迟钝,食欲减退,伴有毛色暗淡无光泽,松散,大便稀软等肝郁证表现。逍遥散组和氟西汀组上述反应明显低于模型组,且两药物组间无显著性差异(P>0.05)。而正常对照组未见异常行为状态。各组间体重增长存在显著差异(P=0.017),模型组生长较缓慢,逍遥散组和氟西汀组服药后体重增长缓慢的情况得到改善,且与模型组有显著差异(P=0.000)。糖水消耗实验提示各组间糖水偏好存在显著性差异((P=0.000),模型组的糖水偏好度明显小于其他组。旷场实验发现模型组大鼠的直立次数和爬格数均显著低于正常组(P=0.000),逍遥散组和氟西汀组则显著优于模型组,但和正常组比较仍有差异(P=0.000)。说明孤养加CUMS确能造成大鼠的肝郁证,能有效的模拟临床中肝郁证兴趣丧失、快感缺乏等症状。
2、获得了高质量的蓝斑组织蛋白质组2-DE凝胶电泳图像。经2-DE分离和对凝胶图像的软件分析,发现了21个蛋白质斑点在三组间(正常组,模型组,逍遥散组)有差异表达。
3、差异蛋白质斑点的质谱检测：出峰率达100%,经过对PMF的分析和数据库检测,确定肝郁证模型大鼠中表达具有显著性差异的蓝斑组织蛋白质17个。
4、血清中T3和T4含量在模型组中最高,逍遥散组和氟西汀组次之,正常组中含量最低(P=0.000),TSH含量则在各组大鼠间的差异均无统计学意义(P=0.740)。
5、HE染色显示各组大鼠蓝斑无明显的形态学改变。
6、IHC检测发现模型组蓝斑Laxetin、Sirt2和TTR的阳性神经元数目均小于正常组,染色强度减弱,平均光密度值也低于正常组。逍遥散组和氟西汀组则可以改善这种情况。
7、WB检测模型组Laxetin、Sirt2和TTR的表达量均低于正常组,逍遥散组和氟西汀组则较模型组表达增加。
8、运用RT-PCR技术检测Laxetin、Sirt2和TTR的mRNA在LC中的表达,发现与正常组比较,模型组表达量均减少,逍遥散组和氟西汀组则较模型组升高。
结论：
对肝郁证孤养加CUMS动物模型进行了蓝斑的蛋白质组的研究,通过分析模型大鼠蓝斑组织蛋白质组的差异表达,获得和肝郁证动物模型密切相关的差异蛋白21个,其中17个可以获得数据库的匹配信息,确定蛋白质名称。我们在这17个蛋白质中选取了Laxetin、Sirt2和TTR这三种蛋白进行进一步的验证。这3种蛋白双向电泳结果提示Latexin和TTR在模型组表达下降,Sirt2在模型组表达上升。我们又采用IHC、WB、RT-PCR三种实验技术同时证明在肝郁证中Laxetin、Sirt2和TTR蛋白表达下降,且逍遥散和氟西汀可以改善这一情况,提示这三种蛋白参与了肝郁证的发病过程,且逍遥散和氟西汀均对其有效,疗效无显著差异。同时提示双向电泳鉴定出的蛋白表达情况只是前期的一种提示,并不一定是100%匹配的,这样我们后面采用三种不同技术验证3种蛋白的表达增加了结果的可信度。该结果为进一步研究肝郁证的分子机制提供了理论基础,也使肝郁证的实质研究有了进一步的发展。但关于这三种蛋白质和肝郁证之间的直接关系尚未明确验证和阐释,有待进一步研究。
Research background:
Syndrome differentiation and treatment are the characteristic and the essence of the Traditional Chinese Medicine.It emphasizes the personalized thinking of TCM."Syndrome" is a unique concept of TCM, it refers to the pathological generalization of the location, etiology, nature and the progression of diseases.Syndrome is a state of our body caused by internal and external factors, it is changing with the development of disease.Syndrome is conclusion about the current essence of the disease.So, the study of nature of disease is the central content of the modernization of TCM.
In recent years,with the draft of the human genome has been completed,the focus of research is moving beyond genomics to proteomics.Protein has been playing an increasingly important role in the development of disease.This makes Proteomics quite valuable in the study of human diseases.As a new subject,proteins research the composition and of protein and its dynamic variety from the whole to grasp the whole situation of the physiological and biochemical process in the disease.Proteomics is an new research field that focuses on a whole set of proteins in a cell or a tissue of an organism.lt explains and clarifies the basic rules of the formation and development of Syndrome.It has overall and dynamic characters,and this is its core idea and it has its own theory and technology traits.From these points,Proteomics is very similar to the TCM theoretical system of the overall concept and individualization.This kind of research idea coincides with the characters of TCM.So this idea has obvious characters of Chinese medicine science.
Liver depression syndrome is one of the common diseases which is caused by the dysfunction of liver and with the characters of depression,choking sensation in chest and irritable.Clinical epidemiology survey showed that liver diseases in the the viscera account for40%of the overall disease.Liver depression syndrome is the core syndrome of the liver disease and play an important role in the pathogenesis of the liver disease.Therefore,the nature of liver depression syndrome is always the hot topic in the area of Combine traditional Chinese and western medicine.There have been more and more researches about nature of the liver depression syndrome in recent years.Some preliminary research suggests that liver depression syndrome has modern pathophysiology basis and partly explain the scientificalness of TCM theory.We have achieved some stage achievements.Some researches indicate that Liver depression syndrome is likely to result from regulating function disorder of high nervous centre induced by negative psychic stress in which pathological changes of multi-system including nerve,endocrine,circulation,digestion,immunity,feeling and motion etc are involved.In recent years,the study of HPA and LC-NE axis has been developed rapidly.We seminar previously discovered liver depression syndrome can cause the up regulation of TH and c-fos in LC.This proved the relationship between LC and liver depression syndrome.
Liver depression syndrome is one of the classic syndromes of liver disease of TCM.The research about its prescription and syndrome is always the most important aspect.The TCM Syndrome research has two feartures.One is to establish corresponding treatment through the result of syndrome differentiation,and the other is to infer the mechanism and symptoms of the disease from the composition and effect of the prescription.In theory,every prescription has its own applicable syndromes and only when the effect of prescription is appropriate for the mechanism of the disease,effect of the prescription can achieve optimal.Through this characteristic,we can establish the pre-determined animal disease models and then interfere them with the pre-determined prescription.After that, we select some abnormal indicators related to the disease and reaearch the animal models that are interfered to estimate whether the disease models are our pre-determined or not.At the same time,in the circumstance that the validation of the animal disease model is good,we observe and study some abnormal indicators and make sure the prescription we select is effect for this disease.
Therefore, we hope to provide further evidence for the correlation of liver depression syndrome and LC and lay a solid foundation for the further study of the nature of liver depression syndrome by research into LC according to the methods of proteomics.Meanwhile, we selected some proteins and used xiaoyaosan to disprove it.Fluoxtine was selected as the positive-controlled medicine for its classic anti-depression effect.
Objective:
To set up the rat model of liver depression syndrome using the method of separation and chronic unpredictable mild stress to find the differentia of general condition and behaviorististics and from the point of proteomics,find the differentially expressed protein in the rat model of liver depressiom.And select the protein which we are interested in to verify.To discover the proteins related to liver depression syndrome from the reaearch of rat model and lay the foundation for the microcosmic differentiation indicatoers system of syndrome.At the same time, to provide technical and theoretical support for the comprehensive investigation on the related proteins from the point of clinical diseases.To explain the essence of liver depression syndrome and to study the clinical effect and mechanism of xiaoyaosan treating the it by comparing the differential expression proteins in the group of xiaoyaosan,fluoxetine and the model group.
Methods:
This study established the rat model of liver depression syndrome by the method of separation and chronic unpredictable mild stress(CUMS).We used two dimensional gel electrophoresis(2-DE)to sepatate the LC proteins,combining with matrix assisted laser desorption time-of-flight mass spectrometry(MALDI-OF-MS),to analyse the differential expression proteins in rat LC between the model group and the normal group.
1. Established the rat model of liver depression syndrome by the method of separation and CUMS.
We established two times of the rat model.The first time is for detection and identification to the differential proteins, the second time is for validation.We used the method of separation and CUMS according to the related literature reports. Eighteen female SD rats with SPF level and were into three groups according to a completely random method.Those were normal control group,liver depression syndrome model group,xiaoyaosan group and fluoxetine group.In each group, there were six rats.(in the second time,there were72rats and were randomly divided into four groups.) Except normal group,rats of other groups were feed separately and were induced by a group of CUMS2times every day for three weeks.Xiaoyaosan group was combined with the interferon of xioayaosan on the basis of the model rats and fluoxetine group with fluoxetine intervention.At the same time, the normal group was feed freely and collectively.
2. The extraction of protein sample and sample mix.
Grinded the LC organization using the liqid nitrogen and lysed the LC cells at a low tempreture.We extracted proteins from LC and made protein quantification by the method of BCA.And mixed the LC regnization in the same group according to the weight.
3.2-DE separation of LC.
We introduced the methods of salt brige and low voltage desalination on the basis of conventional separation technology of proteins to future optimize this technology.The samples were pair-matched.We made the2-DE separation for all the groups and repeated for three times.
4. Gel staining and image analysis.
A new kind of colloidal dye technology was used on the gel we obtained from the2-DE separation.On the one hand,this method can improve the sensitivity of gel staining,on the other hand,it can reduce the interference in the later mass-spectrometric detection.After dyeing and dehydration,the gels were scanned by optical density transmission scanners and the images were got. We used the software of PDquest7.0to analyze the images of gels and got the quantity of each protein expression,soelectric point and the molecular weight of proteins and so on.The protein spot whose expression has more than two times difference was defined to differentially-expressed protein,the results were automatically generated by the software and then were verified manually.
5. The mass spectrometry identification and database confirm of differentially expressed protein spots.
To the differentially expressed protein spots which we received,we applied MALDI-TOF-MS to make the detection of peptide mass figerint(PMF).We cut out the protein spots first and then got the PMF of every protein spot by the steps of water-washing, decolorizing, reduction and alkylation, digestion, extraction, sample and mass spectrometry.After these, we searched major biological and protein-related database by the software of Mascot, to find the proteins which are matched with the PMF we have got and know about the related information.
6. CLIA to test T3, T4and TSH levels of serum in different groups.
7. HE stain to observe morphological changes of LC.
8. Immunohistochemical method to detect the expression changes of the protein we choose in LC and analyze the results by Imageproplus6.0software.
9. Western blot method to detect the expression changes of the protein we choose in LC.
10. RT-PCR technology to detect the expression changes of total RNA of the gene we choose in LC.
11. Statistical analysis.
The experimental results are expressed by x±s. SPSS13.0software was applied for it.ANOVA of repeated measures was applied for the weight changes.For the other indicators, the mean comparison of multiple samples used One Way ANOVA to analyse.When the variance was homogeneous, Least-significant difference (LSD) was applied for multiple comparison and when the variance was heteroscedastic, Tamhane's T2was applied for multiple comparison and the value of P≤0.05would mean significant difference.
Results:
1. We made the rat model of liver depression syndrome succeedly.During the3weeks we interfered them by CUMS procedures,the model rats first were easily angery and then displayed the typical appearance such as low activity,slow reaction,reduces food and drink.Rats from xiaoyaosan group and fluoxtein group also showed some above abnormalities,but they were not obvious.There were no difference between the two medicine groups.Rats in normal group lived well.The rats'weight increase was significantly different between groups(P=0.017).It showed rats in model group grow slowest,while rats in xiaoyaosan group and fluoxetine group grow more than them.Fluid consumption test reavealed that the model group lose appetite for sweet water after3weeks.Statistics showed that there were differences between the three groups(P=0.000).The open field test reavealed that the erect times and travelling grids both reduced in model group and had statistical differences(P=0.000),xiaoyaosan group and fluoxetine group were better than it,but still have a gap with the normal group(P=0.000).The results showed that separation and CUMS could eatablish the model of liver depression syndrome succeedly and simulate clinical symptoms of liver depression syndrome such as interest loss and anhedonia.
2.2-DE was used to separate the whole proteins of LC and the ideal2-DE maps were obtained.Tweenty one differential protein spots were checked out in the three groups(normal, model and xiaoyaosan group).
3. We found seventeen differential proteins by the mass spectrometry identification and database confirm of differentially expressed protein spots.
4. T3and T4levels in serum was highest in the model group and lowest in the normal group, the levels in xiaoyaosan group and fluoxetine group were between the two groups (P=0.000).TSH levels of serum in all the groups were not statistically significant (P=0.740).
5. HE staining showed no obvious morphological change of locus coeruleus in all of groups.
6. Expression results of Immunohistochemical detection of LC showed that the number and mean density of Laxetin,Sirt2and TTR positive cells in model group were lower than others(P<0.05).
7. Expression results of Weatern Blot showed that the expression of Laxetin, Sirt2and TTR were all lower than others(P<0.05).
8. The expression of LaxetinmRNA, Sirt2mRNA and TTRmRNA by RT-PCR was observed that all were reduced in model group while xiaoyaosan group and fluoxetine group were higher than it.
Conclusion:
We eatablished the rat model of liver depression syndrome by separation and CUMS and researched the LC proteomics.21differential proteins related to liver depression syndrome were obtained,among them17proteins could be matched with the information in database to determine their names.Then,we selected the proteins of Latexin,Sirt2and TTR from the17proteins to further verified.Among the3proteins,2-DE results suggested that the expression of Latexin and TTR were reduced in model group and Sirt2was up-regulated.Then IHC,WB and RT-PCR technologys were used to prove that the expression of Laxetin,Sirt2and TTR was reduced in liver depression syndrome and xiaoyaosan,fluoxetine could improve this condition. The results revealed the three proteins involved in the process of liver depression syndrome.Xiaoyaosan and fluoxetine play the same role in it and have no differences. This result suggests that the expression of proteins identified by2-DE is just a prompt and is not necessarily a100%exact match.So we used three other methods to further verify the expression of the three proteins to increase the credibility.The results provided theoretical basis for the further research of the molecular mechanisms of liver depression syndrome, and make the essence study of liver depression syndrome have a further development.But the direct relationship between the three proteins and liver depression syndrome has not yet validated and elaborated. This remains to be further research.
引文
[1]祁明浩.基因芯片技术在中医证研究中的思考与应用[J].中医药学刊,2006,24(11)：2022-2024.
[2]刘为民,姚乃礼,吴志奎,等.中医证候学研究与证候蛋白质组学[J].中医药学报,2003.31(3)：1.
[3]申定珠,李家邦,蒋荣鑫,等.证候蛋白质组学与中医证候学相关性探讨[J].中国中西医结合杂志,2006,26(4)：366-368.
[4]蔡定芳,沈自尹.中西医结合神经内分泌免疫网络研究的思考[J].中国中西医结合杂志,1997,17(7)：442-445.
[5]吕志平,刘承才.“肝郁”大鼠血浆TXAZ, PGI水平与肝微循环变化及逍遥散作用[J].中国微循环,2000,4(3)：160-161.
[6]邹襄谷,陈文发.中药对慢性胃病脾虚兼肝郁证的胃电影响[J].福建中医学院学报,1995,5(3)：22-25.
[7]蔡淦,张玉喜,刘群,等.肝郁证、脾虚证、肝郁脾虚证下丘脑、蓝斑CRF含量变化研究[J].上海中医药杂志,2006,40(8)：1-3.
[8]张虹,王明军.逍遥散对肝郁证大鼠脑内神经递质的影响[J].中医药刊,2006,24(7)：1331-1332.
[9]熊静悦,曾南,张崇燕.逍遥散对CUMS模型大鼠行为学及脑内单胺类神经递质的影响[J].现代生物医学进展,2007,7(11)：1635-1639.
[10]丁杰,陈家旭,梁媛.逍遥散对肝郁脾虚证模型大鼠外周促肾上腺皮质激素_皮质酮的调节作用[J].中华中医药杂志,2009,24(11)：1436-1439.
[11]杨东英,陆小兵,姚建新,等.逍遥散联合帕罗西汀对老年抑郁症疗效及HPA轴功能的影响[J].中国民康医学,2010,22(17)：2224-2226.
[12]Craig WB, Barry DW. The locus coeruleus-noradrenergic system:modulation of behavioral state and state- dependent cognitive process. Brain Research Reviews,2003,42:33-84.
[13]陈泽奇,陈国林,胡随瑜,等.肝气郁结证辅助实验诊断指标的初步研究[J].中国现代医学杂志,2001,11(12)：8.
[14]亢泽峰,庄曾渊,万素君,等.血虚证大鼠视网膜病理改变的研究[J].中国中医基础医学杂志,2001,23(7)：43-46.
[15]苗明三.实验动物与动物实验技术[M].北京：中国中医药出版社,1997：300.
[16]陈松,李家邦,朱双罗,等.肝郁证T、B淋巴细胞活性改变及疏肝治疗影响的研究[J].中国中医药学报,2001,(21)：7.
[17]刘素蓉,曹瑾,吴喜利.应用甲状腺素片及饥饱失常法建立肝郁证大鼠模型的研究[J].西安交通大学学报医学版,2009,30(2)：251-253.
[18]金光亮,南睿,郭霞珍.慢性应激肝郁证大鼠模型的建立[J].北京中医药大学学报,2003,26(2)：18.
[19]金光亮,王胜兰.关于建立肝郁证动物模型的思考[J].山东中医药大学学报,2004,28(6)：408.
[20]于琦.四逆散、归脾汤与温胆汤对慢性应激肝郁模型大鼠行为学的影响[J].广州中医药大学学报,2009,26(2)：148-150.
[21]周力,蒲琴,申理,等.利用不良情志建立肝郁证动物模型初探[J].中国药理与临床,2008,24(3)：114-116.
[22]李峰,杨维益,梁嵘,等.从中医学看肝脏调节应激反应的作用[J].北京中医药大学学报1998,21(5)：21-23.
[23]吴先哲.论心理应激与肝失疏泄的辨证关系[J].时珍国医国药杂志,2004,15：445-447.
[24]岳广欣,陈家旭,王竹风.肝主疏泄的生理学基础探讨[J].北京中医药大学学报,2005,28(2)：1-4.
[25]孙英霞,王海军,赵艳,等.情志致病因素与规律研究综述分析[A].中华中医药学会中医基础理论分会第三届学术年会论文集[C].2009.
[26]乔明琦,王文燕,张惠云,等.肝气逆肝气郁两证病因流行病学调查及情志致病方式研究[J].中国中西医结合杂志,2007,27(2)：117-119.
[27]钟小兰,吕志平.肝郁证与慢性心理应激的关系思考[A]“情绪与健康和疾病及其中医药干预”国际学术研讨会暨中医基础理论分会第一届学术年会论文集[C].2007.
[28]陈泽奇,陈国林,石林阶,等.肝气郁结患者血浆L-ENK, AVP, ANP含量分析[J].湖南中医学院学报,1997,17(3)：37.
[29]陈泽奇,陈国林,李学文,等.肝气郁结证患者血浆抗利尿激素的变化[J].华人消化杂志,1998,6(6)：495.
[30]陈青红,陈家旭,徐洪雁,等.肝郁证植物功能与情绪状态的评估[J]北京中医药大学学报,2004,27(6)：65-68.
[31]乔明琦,张慧云,陈雨振,等.肝郁证动物模型研究的理论思考[J].中国医药学报,1997,12(5)：42-44.
[32]毛海燕,叶林,叶向荣.肝郁证大鼠中枢神经递质变化的观察[J].福建中医药,2002,33(2)：17-18.
[33]须惠仁.肝郁证的动物实验研究-激怒刺激对大白鼠血液流变学的影响[J].中医杂志,1991,32(6)：44-47.
[34]王希浩,黄保民,张关亭,等.激怒雌性大鼠内分泌的改变及中药的干预作用[J].四川中药,2003,21(5)：9-10.
[35]文哲双,王志忠,朱毅.肝郁证患者血清T、E2、PRL检测及其临床意义[J].湖南中医学院学报,2000,2(2)：27.
[36]常德贵,王峥屹,祝彼得,等.疏肝理气活血法对肝郁气滞大鼠、阴茎海绵体PDE活性影响的实验研究[J].中华男科学,2004,10(1)：71.
[37]金戈,董晓丽,明海霞.电刺激单双侧迷走神经对肝郁证大鼠血液流变学的影响[J].中国老年医学杂志,2012,32(19)4237-4238.
[38]王希浩,郝长源,罗伟.肝郁证月经病血液流变性的改变和意义[J].中国研 究,1997,10(1)：21-22.
[39]吕志平,刘承才.肝郁致瘀机理探讨[J].中医杂志,2000,41(6)：367-368.
[40]张沁园.肝失疏泄对小肠吸收功能影响的实验研究[J].北京中医药大学学报,1999,22(4)：31.
[41]肖桂林,金益强,鄢东红,等.肝郁脾虚证实验诊断指标的研究[J].湖南中医学院学报,1998,18(2)：4-5.
[42]陈泽奇,李学文,陈国林,等.肝气郁结证患者血清胃泌素含量分析[J].湖南中医学院学报,1998,18(1)：3.
[43]毛海燕.肝郁证大鼠肝线粒体膜流动性、血浆胃动素及血清胃泌素的变化及意义[J].福建中医药,2003,34(3)：42.
[44]陈家旭,李伟,赵歆,等.慢性束缚应激模型大鼠海马脑啡肽mRNA和前强啡肽mRNA的表达及中药复方的影响[J].中国应用生理学杂志,2005,21(2)：121-125.
[45]严灿,高敏.肝郁证免疫机能改变机制的临床与实验研究[J].中医研究,1995,8(6)：18-20.
[46]杨冬花,李家邦,郑爱华,等.肝气郁结证患者T细胞免疫功能的改变及柴胡疏肝散的治疗作用[J].陕西中医,2006,27(3)：374-375.
[47]赵益业,刘承才.肝郁证的免疫学探讨[J].山东中医药大学学报,1997,21(1)：28-32.
[48]陈松,李家邦,朱双罗,等.肝郁证T、B淋巴细胞活性改变及疏肝治疗影响的实验研究[J].湖南中医学院学报,2001,2 1(2)：7-8.
[49]俞亚琴,郭合钩.肠道易激征患者的中医辨证与微量元素关系的实验研究[J].中医药研究,1997,13(4)：46.
[50]陈建伟,李祥,陈进,等.正常人与肝气郁结证人指甲中无机元素的比较分析[J].广东微量元素科学,2001,8(11)：34-37.
[51]吕志平,刘承才.肝郁动物模型肝细胞线粒体超微结构观察[J].湖南中医杂 志,2000,16(5)：61-62.
[52]吕志平.“肝郁”大鼠的脂质过氧化反应及逍遥散的保护作用[J].山东中医学院学报,1995,19(3)：199.
[53]敖海清,徐志伟,严灿,等.柴胡疏肝散及逍遥散对慢性心理应激大鼠血清皮质酮及胃肠激素的影响[J].中药新药与临床病理,2007,18(4)：289-291.
[54]于琦,金光亮.四逆散、逍遥散与四君子汤对慢性应激肝郁模型大鼠行为学影响的研究[J].天津中医药,2007,24(6)：509-511.
[55]严灿,徐志伟,吴丽丽,等.加味四逆散抗慢性心理应激损伤的机理研究对下丘脑促肾上腺皮质激素释放激素及环核营酸系统的影响[J].广州中医药大学学报,2004,21(6)：466-469.
[56]谢忠礼,李杰,王兴华.加味四逆散对慢性应激模型大鼠下丘脑单胺类神经递质的影响[J].中国实验方剂学杂志,2008,14(1)：50-52.
[57]Aebersold R. Constellations in a cellular universe[J]. Nature,2003,422:115-116.
[58]丘宗荫,尹一兵.临床蛋白质组学[M].北京：科学出版社,2008：329.
[59]宋为民,王明艳,徐力.基因组学是中医现代化的最佳切入点.南京中医药大学学报,1999,15(4)：193-195.
[60]钟小兰,吕志平,钱令嘉,等.肝郁证模型大鼠血清蛋白质组的差异表达研究[J].中华中医药杂志,2006,21(7)：399-401.
[61]刘丽丽,马增春,王宇光,等.四物汤对环磷酞胺致血虚证小鼠骨髓蛋白质组的影响[J].中国中药杂志,2006,31(14)1172-1175.
[62]谢文光,马晓昌,邵宁生,等.赤芍治疗热毒血癖证的血清蛋白质组变化的初步研究[J].中国中西医结合杂志,2005,25(6)：520-524.
[63]肖献忠.病理生理学[M].北京：高等教育出版社,2004.
[64]丁秀芳,陶杨,张丽华,等.慢性应激肝郁模型大鼠蓝斑CRF、c-fos的表达及逍遥散的干预作用[J].热带医学杂志,2012,12(6)：690-693.
[65]Rita J.Valentino, Elisabeth Van Bockstaele.Convergent regulation of locus coeruleus activity as an adaptive response to stress[J].European Journal of Pharmacology,2008,(583):194-203.
[66]C.A.Barnes,M.Pomeiano,Neurobilolgy of the locus coeruleus[J].Prog Brain Res,1991,88:307-321.
[67]R.J.Valentino,G.Aston-Joned.Physiological determinants of locus coeruleus discharge in F.E.Bloom[J].Kupfer Psychopharmacology:The Fourth Generation of Progress,Raven Press,1995,373-385.
[68]Marain Joels Tallie Z.Baram.The neuron-symphony of stress[J].Nature Reviews Neuroscience,2009,10:459.
[69]J.N.Cunningham, R.Nissen, L.P.Renaud.Norepinephrine injections in diagonal band of Broca selectively reduced the activity of vasopressin supraoptic neurons in the rat [J].Brain Res,1993, (610):152-155.
[70]Beverly A.S.Rey, Rita J, Valentino and Elisabeth J.Van Bockstaele.Stress-Induced Intracellular Traffickong of Corticotropin-Releasing Factor Recepters in Rat Locus Coeruleus Neurons [J].Endocrinology, 2008,149(1):122-130.
[71]S.Ma,S.W.Mifflin,J.T.Cunningham and D.A.Morilak.Chronic intermittent hypoxia sensilitizes acute hypothalamic-pituitary-adrenal stress reactivity and Fos induction in the rat locus coeruleus in response to subsequent immobilization stress[J].Systems neuroscience,2008,(154):1641-1642.
[72]魏伟,吴希美,李元建.药理实验学方法第四版[M].人民卫生出版社,2010：69-72.
[73]Toth E, Gersner R, Wilf-Yarkoni A, Raizel H, Dar DE, Richter-Levin G et al. Age-dependent effects of chronic stress on brain plasticity and depressive behavior[J].J Neurochem,2008,107:522-532.
[74]Lewitus GM, Wilf-Yarkoni A, Ziv Y, Shabat-Simon M, Gersner R,Zangen A et al. Vaccination as a novel approach for treating depressive behavior[J]. Biol Psychiatry 2009,65:283-288.
[75]孔令玲.大鼠脑蓝斑核固定方法的实验研究[J].医学研究杂志,2011,40(4)：95-97.
[76]韩俊英,曾瑞萍.荧光定量PCR技术及其应用[J].国外医学遗传学分册,2000,23(3)：177.
[77]Wall SJ, EdwardDR.Quantitative reverse transeription-polymerase chain reaction (RT-PCR):a comparison of prime-dropping, competive, and real-time RT-PCRs [J] Anal Bioehem,2002,300(2):269-273.
[78]Livak KJ, SehmittgenTD.Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method [J].Mrthods,2001, 25(4):402-408.
[79]陆滨.抑郁症和焦虑症的心理社会因素对照研究[J].中国临床康复,2002,6(13)：1964-1967.
[80]乔明琦,张慧云,陈雨振,等.肝郁证动物模型研究的理论思考[J].中国医药学报,1997,12(5)：42-44.
[81]郑吉民,罗仁,陈健,等.试探肝郁证的临床规律[J].中医杂志,1989,(10)：39.
[82]D Taliaz, N Stall, DE Dar et al. Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis [J]. Molecular Psychiatry,2010,15:80-92.
[83]Yadid G, Nakash R, Deri I,et al..Elucidation of the neurobiology of depression: insighis from a novel genetic animal model [J].Prog Neurobiol,2000,62(4): 353-378.
[84]贾广成,郑兴宇,周玉枝,等.逍遥散对CUMS模型大鼠行为学及血浆内单胺类神经递质的影响[J].2011,17(6)：136-140.
[85]Wang S,Hu S,Zhang C,Qiu J,Li Y. Effect of Chaihu Shugan San and its components on expression of ERK1/2 mRNA in the hippocampus of rats with chronic mild unpredicted stress depression[J]. Zhong Nan Da Xue Xue Bao. Yi Xue Ban.2011,36(2):93-100.
[86]包新民,舒斯云.大鼠脑立体定位图谱[M].北京：人民卫生出版社,1991.
[87]Chrousos GP.The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation [J].N Engl J Med,1995,332(20):1351-1362.
[88]Pallar s I, Bonet R, Garca-castellanos R, et al.Structure of human carboxypeptidaseA4 with its endogenous protein inhibitor, latexin [J]. PNAS, 2005,102(11):3978-3983.
[89]Normant,E, Martres,M P,Schwartz,J C,et al. Purification, cDNA cloning, functional expression, and characterization of a 26-kDa endogenous mammalian carboxypeptidase inhibitor[J]. Proc Natl Acad Sci U S A,1995,92(26):12225-12229.
[90]Mirnics,Z K,Mirnics,K,Terrano,D et al. DNA microarray profiling of developing PS1-deficient mouse brain reveals complex and coregulated expression changes[J].2003,8(10):863-878.
[91]Hatanaka, Y,Uratani, Y,Takiguchi-Hayashi, K et al. Intracortical regionality represented by specific transcription for a novel protein, latexin[J]. 1994,6(6):973-982.
[92]Aagaard A, Listw an P, Cow ieson N, et a.l An inflammatory role for the mammalian carboxypeptidase inhibitor latexin:relationship to cystatins and the tumor suppressor TIG1[J]. S tructure,2005,13(2):309-317.
[93]李圣青,刘阿茹,欧阳海峰,等.急性肺栓塞后肺泡巨噬细胞Latexin表达上调及其对炎症的影响[J].陕西医学杂志,2007,36(9)：1113-1117.
[94]杨小丽,宣强,莫曾南.前列腺增生上皮对间质细胞Latexin基因表达的影响 [J].广西医学,2010,32(6)：633-635.
[95]Minghao Jin,Mami ishida,Yuko Katoh-Fukui,et al.Reduced pain sensitivity in mice lacking latexin,an inhibitor of metallocarboxypeptidase[J].Brain Research,2006,1075(1):117-121.
[96]North BJ,Marshall BL,Borra MT,et al.The human Sir ortholog,SIRT2, is an NAD+ dependent tubulin deacelase[J].Mol cell,2003,11:437-444.
[97]林锐波,王伟,傅玉才,等.Sirtuin基因家族与心血管疾病[J].岭南心血管病杂志,2010,16(1)：63-65.
[98]WANG F,NGUYEN M,QIN F X,et al.Sirt2 deacetylates FOXO3a in response to oxidative stress and caloric restriction [J].Aging Cell,2007,6(4): 505-514.
[99]Li W,Zhang B,Tang J.et al.Sirtuin 2,a Mammalian Homolog of Yeast Silent Information Regulator-2 Longevity Regulator, Is an Qligodendroglial Protein That Decelerates Cell Differentiation through Deacetylating alpha-Tubulin[J].J Neurosci,2007,27(10):2606-2616.
[100]Yanze Li,Haruka Matsumori,Yuji Nakayama,et al. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis[J]. Genes Cells,2011,27(1):34-45.
[101]Vanita Chopra,Luisa Quinti,Jinho Kim, et al. The Sirtuin 2 Inhibitor AK-7 is Neuroprotective in Huntington Disease Mouse Models[J].Cell Rep,2012,2(6):1492-1497.
[102]Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science,2004,305(5686): 1010-1013.
[103]Refai E,Dekki N,Yang SN,et al.Transthyretin constitutes a functional component in pancreatic beta-cell stimulus-secretion coupling[J].Proc Natl Acad Sci USA,2005,102:17020-17025.
[104]Dwulet FE,BensonMD.Characterization of transthyretin (prealbumin)vaiant associated amyloidotic polyneuiathy typeⅡ[J].J Clin Invest,1986,78(4): 880-886.
[105]Sousa MM,Berglund L,Saraiva MJ.Trnasthyretin in high density lipoproteins:
[106]Association with apolipoporteniA-Ⅰ [J].Joumal of Lipid Research,2000,41(1): 58-65.
[107]李钧敏,林启山,刘国诊,等.人血浆转甲状腺素蛋白的提纯及其对肝癌细胞生长的抑制作用[J].中国肿瘤生物治疗杂志1999,6(2)：97-101.
[2]刘为民,姚乃礼,吴志奎,等.中医证候学研究与证候蛋白质组学[J].中医药学报,2003.31(3)：1.
[3]申定珠,李家邦,蒋荣鑫,等.证候蛋白质组学与中医证候学相关性探讨[J].中国中西医结合杂志,2006,26(4)：366-368.
[4]蔡定芳,沈自尹.中西医结合神经内分泌免疫网络研究的思考[J].中国中西医结合杂志,1997,17(7)：442-445.
[5]吕志平,刘承才.“肝郁”大鼠血浆TXAZ, PGI水平与肝微循环变化及逍遥散作用[J].中国微循环,2000,4(3)：160-161.
[6]邹襄谷,陈文发.中药对慢性胃病脾虚兼肝郁证的胃电影响[J].福建中医学院学报,1995,5(3)：22-25.
[7]蔡淦,张玉喜,刘群,等.肝郁证、脾虚证、肝郁脾虚证下丘脑、蓝斑CRF含量变化研究[J].上海中医药杂志,2006,40(8)：1-3.
[8]张虹,王明军.逍遥散对肝郁证大鼠脑内神经递质的影响[J].中医药刊,2006,24(7)：1331-1332.
[9]熊静悦,曾南,张崇燕.逍遥散对CUMS模型大鼠行为学及脑内单胺类神经递质的影响[J].现代生物医学进展,2007,7(11)：1635-1639.
[10]丁杰,陈家旭,梁媛.逍遥散对肝郁脾虚证模型大鼠外周促肾上腺皮质激素_皮质酮的调节作用[J].中华中医药杂志,2009,24(11)：1436-1439.
[11]杨东英,陆小兵,姚建新,等.逍遥散联合帕罗西汀对老年抑郁症疗效及HPA轴功能的影响[J].中国民康医学,2010,22(17)：2224-2226.
[12]Craig WB, Barry DW. The locus coeruleus-noradrenergic system:modulation of behavioral state and state- dependent cognitive process. Brain Research Reviews,2003,42:33-84.
[13]陈泽奇,陈国林,胡随瑜,等.肝气郁结证辅助实验诊断指标的初步研究[J].中国现代医学杂志,2001,11(12)：8.
[14]亢泽峰,庄曾渊,万素君,等.血虚证大鼠视网膜病理改变的研究[J].中国中医基础医学杂志,2001,23(7)：43-46.
[15]苗明三.实验动物与动物实验技术[M].北京：中国中医药出版社,1997：300.
[16]陈松,李家邦,朱双罗,等.肝郁证T、B淋巴细胞活性改变及疏肝治疗影响的研究[J].中国中医药学报,2001,(21)：7.
[17]刘素蓉,曹瑾,吴喜利.应用甲状腺素片及饥饱失常法建立肝郁证大鼠模型的研究[J].西安交通大学学报医学版,2009,30(2)：251-253.
[18]金光亮,南睿,郭霞珍.慢性应激肝郁证大鼠模型的建立[J].北京中医药大学学报,2003,26(2)：18.
[19]金光亮,王胜兰.关于建立肝郁证动物模型的思考[J].山东中医药大学学报,2004,28(6)：408.
[20]于琦.四逆散、归脾汤与温胆汤对慢性应激肝郁模型大鼠行为学的影响[J].广州中医药大学学报,2009,26(2)：148-150.
[21]周力,蒲琴,申理,等.利用不良情志建立肝郁证动物模型初探[J].中国药理与临床,2008,24(3)：114-116.
[22]李峰,杨维益,梁嵘,等.从中医学看肝脏调节应激反应的作用[J].北京中医药大学学报1998,21(5)：21-23.
[23]吴先哲.论心理应激与肝失疏泄的辨证关系[J].时珍国医国药杂志,2004,15：445-447.
[24]岳广欣,陈家旭,王竹风.肝主疏泄的生理学基础探讨[J].北京中医药大学学报,2005,28(2)：1-4.
[25]孙英霞,王海军,赵艳,等.情志致病因素与规律研究综述分析[A].中华中医药学会中医基础理论分会第三届学术年会论文集[C].2009.
[26]乔明琦,王文燕,张惠云,等.肝气逆肝气郁两证病因流行病学调查及情志致病方式研究[J].中国中西医结合杂志,2007,27(2)：117-119.
[27]钟小兰,吕志平.肝郁证与慢性心理应激的关系思考[A]“情绪与健康和疾病及其中医药干预”国际学术研讨会暨中医基础理论分会第一届学术年会论文集[C].2007.
[28]陈泽奇,陈国林,石林阶,等.肝气郁结患者血浆L-ENK, AVP, ANP含量分析[J].湖南中医学院学报,1997,17(3)：37.
[29]陈泽奇,陈国林,李学文,等.肝气郁结证患者血浆抗利尿激素的变化[J].华人消化杂志,1998,6(6)：495.
[30]陈青红,陈家旭,徐洪雁,等.肝郁证植物功能与情绪状态的评估[J]北京中医药大学学报,2004,27(6)：65-68.
[31]乔明琦,张慧云,陈雨振,等.肝郁证动物模型研究的理论思考[J].中国医药学报,1997,12(5)：42-44.
[32]毛海燕,叶林,叶向荣.肝郁证大鼠中枢神经递质变化的观察[J].福建中医药,2002,33(2)：17-18.
[33]须惠仁.肝郁证的动物实验研究-激怒刺激对大白鼠血液流变学的影响[J].中医杂志,1991,32(6)：44-47.
[34]王希浩,黄保民,张关亭,等.激怒雌性大鼠内分泌的改变及中药的干预作用[J].四川中药,2003,21(5)：9-10.
[35]文哲双,王志忠,朱毅.肝郁证患者血清T、E2、PRL检测及其临床意义[J].湖南中医学院学报,2000,2(2)：27.
[36]常德贵,王峥屹,祝彼得,等.疏肝理气活血法对肝郁气滞大鼠、阴茎海绵体PDE活性影响的实验研究[J].中华男科学,2004,10(1)：71.
[37]金戈,董晓丽,明海霞.电刺激单双侧迷走神经对肝郁证大鼠血液流变学的影响[J].中国老年医学杂志,2012,32(19)4237-4238.
[38]王希浩,郝长源,罗伟.肝郁证月经病血液流变性的改变和意义[J].中国研 究,1997,10(1)：21-22.
[39]吕志平,刘承才.肝郁致瘀机理探讨[J].中医杂志,2000,41(6)：367-368.
[40]张沁园.肝失疏泄对小肠吸收功能影响的实验研究[J].北京中医药大学学报,1999,22(4)：31.
[41]肖桂林,金益强,鄢东红,等.肝郁脾虚证实验诊断指标的研究[J].湖南中医学院学报,1998,18(2)：4-5.
[42]陈泽奇,李学文,陈国林,等.肝气郁结证患者血清胃泌素含量分析[J].湖南中医学院学报,1998,18(1)：3.
[43]毛海燕.肝郁证大鼠肝线粒体膜流动性、血浆胃动素及血清胃泌素的变化及意义[J].福建中医药,2003,34(3)：42.
[44]陈家旭,李伟,赵歆,等.慢性束缚应激模型大鼠海马脑啡肽mRNA和前强啡肽mRNA的表达及中药复方的影响[J].中国应用生理学杂志,2005,21(2)：121-125.
[45]严灿,高敏.肝郁证免疫机能改变机制的临床与实验研究[J].中医研究,1995,8(6)：18-20.
[46]杨冬花,李家邦,郑爱华,等.肝气郁结证患者T细胞免疫功能的改变及柴胡疏肝散的治疗作用[J].陕西中医,2006,27(3)：374-375.
[47]赵益业,刘承才.肝郁证的免疫学探讨[J].山东中医药大学学报,1997,21(1)：28-32.
[48]陈松,李家邦,朱双罗,等.肝郁证T、B淋巴细胞活性改变及疏肝治疗影响的实验研究[J].湖南中医学院学报,2001,2 1(2)：7-8.
[49]俞亚琴,郭合钩.肠道易激征患者的中医辨证与微量元素关系的实验研究[J].中医药研究,1997,13(4)：46.
[50]陈建伟,李祥,陈进,等.正常人与肝气郁结证人指甲中无机元素的比较分析[J].广东微量元素科学,2001,8(11)：34-37.
[51]吕志平,刘承才.肝郁动物模型肝细胞线粒体超微结构观察[J].湖南中医杂 志,2000,16(5)：61-62.
[52]吕志平.“肝郁”大鼠的脂质过氧化反应及逍遥散的保护作用[J].山东中医学院学报,1995,19(3)：199.
[53]敖海清,徐志伟,严灿,等.柴胡疏肝散及逍遥散对慢性心理应激大鼠血清皮质酮及胃肠激素的影响[J].中药新药与临床病理,2007,18(4)：289-291.
[54]于琦,金光亮.四逆散、逍遥散与四君子汤对慢性应激肝郁模型大鼠行为学影响的研究[J].天津中医药,2007,24(6)：509-511.
[55]严灿,徐志伟,吴丽丽,等.加味四逆散抗慢性心理应激损伤的机理研究对下丘脑促肾上腺皮质激素释放激素及环核营酸系统的影响[J].广州中医药大学学报,2004,21(6)：466-469.
[56]谢忠礼,李杰,王兴华.加味四逆散对慢性应激模型大鼠下丘脑单胺类神经递质的影响[J].中国实验方剂学杂志,2008,14(1)：50-52.
[57]Aebersold R. Constellations in a cellular universe[J]. Nature,2003,422:115-116.
[58]丘宗荫,尹一兵.临床蛋白质组学[M].北京：科学出版社,2008：329.
[59]宋为民,王明艳,徐力.基因组学是中医现代化的最佳切入点.南京中医药大学学报,1999,15(4)：193-195.
[60]钟小兰,吕志平,钱令嘉,等.肝郁证模型大鼠血清蛋白质组的差异表达研究[J].中华中医药杂志,2006,21(7)：399-401.
[61]刘丽丽,马增春,王宇光,等.四物汤对环磷酞胺致血虚证小鼠骨髓蛋白质组的影响[J].中国中药杂志,2006,31(14)1172-1175.
[62]谢文光,马晓昌,邵宁生,等.赤芍治疗热毒血癖证的血清蛋白质组变化的初步研究[J].中国中西医结合杂志,2005,25(6)：520-524.
[63]肖献忠.病理生理学[M].北京：高等教育出版社,2004.
[64]丁秀芳,陶杨,张丽华,等.慢性应激肝郁模型大鼠蓝斑CRF、c-fos的表达及逍遥散的干预作用[J].热带医学杂志,2012,12(6)：690-693.
[65]Rita J.Valentino, Elisabeth Van Bockstaele.Convergent regulation of locus coeruleus activity as an adaptive response to stress[J].European Journal of Pharmacology,2008,(583):194-203.
[66]C.A.Barnes,M.Pomeiano,Neurobilolgy of the locus coeruleus[J].Prog Brain Res,1991,88:307-321.
[67]R.J.Valentino,G.Aston-Joned.Physiological determinants of locus coeruleus discharge in F.E.Bloom[J].Kupfer Psychopharmacology:The Fourth Generation of Progress,Raven Press,1995,373-385.
[68]Marain Joels Tallie Z.Baram.The neuron-symphony of stress[J].Nature Reviews Neuroscience,2009,10:459.
[69]J.N.Cunningham, R.Nissen, L.P.Renaud.Norepinephrine injections in diagonal band of Broca selectively reduced the activity of vasopressin supraoptic neurons in the rat [J].Brain Res,1993, (610):152-155.
[70]Beverly A.S.Rey, Rita J, Valentino and Elisabeth J.Van Bockstaele.Stress-Induced Intracellular Traffickong of Corticotropin-Releasing Factor Recepters in Rat Locus Coeruleus Neurons [J].Endocrinology, 2008,149(1):122-130.
[71]S.Ma,S.W.Mifflin,J.T.Cunningham and D.A.Morilak.Chronic intermittent hypoxia sensilitizes acute hypothalamic-pituitary-adrenal stress reactivity and Fos induction in the rat locus coeruleus in response to subsequent immobilization stress[J].Systems neuroscience,2008,(154):1641-1642.
[72]魏伟,吴希美,李元建.药理实验学方法第四版[M].人民卫生出版社,2010：69-72.
[73]Toth E, Gersner R, Wilf-Yarkoni A, Raizel H, Dar DE, Richter-Levin G et al. Age-dependent effects of chronic stress on brain plasticity and depressive behavior[J].J Neurochem,2008,107:522-532.
[74]Lewitus GM, Wilf-Yarkoni A, Ziv Y, Shabat-Simon M, Gersner R,Zangen A et al. Vaccination as a novel approach for treating depressive behavior[J]. Biol Psychiatry 2009,65:283-288.
[75]孔令玲.大鼠脑蓝斑核固定方法的实验研究[J].医学研究杂志,2011,40(4)：95-97.
[76]韩俊英,曾瑞萍.荧光定量PCR技术及其应用[J].国外医学遗传学分册,2000,23(3)：177.
[77]Wall SJ, EdwardDR.Quantitative reverse transeription-polymerase chain reaction (RT-PCR):a comparison of prime-dropping, competive, and real-time RT-PCRs [J] Anal Bioehem,2002,300(2):269-273.
[78]Livak KJ, SehmittgenTD.Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method [J].Mrthods,2001, 25(4):402-408.
[79]陆滨.抑郁症和焦虑症的心理社会因素对照研究[J].中国临床康复,2002,6(13)：1964-1967.
[80]乔明琦,张慧云,陈雨振,等.肝郁证动物模型研究的理论思考[J].中国医药学报,1997,12(5)：42-44.
[81]郑吉民,罗仁,陈健,等.试探肝郁证的临床规律[J].中医杂志,1989,(10)：39.
[82]D Taliaz, N Stall, DE Dar et al. Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis [J]. Molecular Psychiatry,2010,15:80-92.
[83]Yadid G, Nakash R, Deri I,et al..Elucidation of the neurobiology of depression: insighis from a novel genetic animal model [J].Prog Neurobiol,2000,62(4): 353-378.
[84]贾广成,郑兴宇,周玉枝,等.逍遥散对CUMS模型大鼠行为学及血浆内单胺类神经递质的影响[J].2011,17(6)：136-140.
[85]Wang S,Hu S,Zhang C,Qiu J,Li Y. Effect of Chaihu Shugan San and its components on expression of ERK1/2 mRNA in the hippocampus of rats with chronic mild unpredicted stress depression[J]. Zhong Nan Da Xue Xue Bao. Yi Xue Ban.2011,36(2):93-100.
[86]包新民,舒斯云.大鼠脑立体定位图谱[M].北京：人民卫生出版社,1991.
[87]Chrousos GP.The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation [J].N Engl J Med,1995,332(20):1351-1362.
[88]Pallar s I, Bonet R, Garca-castellanos R, et al.Structure of human carboxypeptidaseA4 with its endogenous protein inhibitor, latexin [J]. PNAS, 2005,102(11):3978-3983.
[89]Normant,E, Martres,M P,Schwartz,J C,et al. Purification, cDNA cloning, functional expression, and characterization of a 26-kDa endogenous mammalian carboxypeptidase inhibitor[J]. Proc Natl Acad Sci U S A,1995,92(26):12225-12229.
[90]Mirnics,Z K,Mirnics,K,Terrano,D et al. DNA microarray profiling of developing PS1-deficient mouse brain reveals complex and coregulated expression changes[J].2003,8(10):863-878.
[91]Hatanaka, Y,Uratani, Y,Takiguchi-Hayashi, K et al. Intracortical regionality represented by specific transcription for a novel protein, latexin[J]. 1994,6(6):973-982.
[92]Aagaard A, Listw an P, Cow ieson N, et a.l An inflammatory role for the mammalian carboxypeptidase inhibitor latexin:relationship to cystatins and the tumor suppressor TIG1[J]. S tructure,2005,13(2):309-317.
[93]李圣青,刘阿茹,欧阳海峰,等.急性肺栓塞后肺泡巨噬细胞Latexin表达上调及其对炎症的影响[J].陕西医学杂志,2007,36(9)：1113-1117.
[94]杨小丽,宣强,莫曾南.前列腺增生上皮对间质细胞Latexin基因表达的影响 [J].广西医学,2010,32(6)：633-635.
[95]Minghao Jin,Mami ishida,Yuko Katoh-Fukui,et al.Reduced pain sensitivity in mice lacking latexin,an inhibitor of metallocarboxypeptidase[J].Brain Research,2006,1075(1):117-121.
[96]North BJ,Marshall BL,Borra MT,et al.The human Sir ortholog,SIRT2, is an NAD+ dependent tubulin deacelase[J].Mol cell,2003,11:437-444.
[97]林锐波,王伟,傅玉才,等.Sirtuin基因家族与心血管疾病[J].岭南心血管病杂志,2010,16(1)：63-65.
[98]WANG F,NGUYEN M,QIN F X,et al.Sirt2 deacetylates FOXO3a in response to oxidative stress and caloric restriction [J].Aging Cell,2007,6(4): 505-514.
[99]Li W,Zhang B,Tang J.et al.Sirtuin 2,a Mammalian Homolog of Yeast Silent Information Regulator-2 Longevity Regulator, Is an Qligodendroglial Protein That Decelerates Cell Differentiation through Deacetylating alpha-Tubulin[J].J Neurosci,2007,27(10):2606-2616.
[100]Yanze Li,Haruka Matsumori,Yuji Nakayama,et al. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis[J]. Genes Cells,2011,27(1):34-45.
[101]Vanita Chopra,Luisa Quinti,Jinho Kim, et al. The Sirtuin 2 Inhibitor AK-7 is Neuroprotective in Huntington Disease Mouse Models[J].Cell Rep,2012,2(6):1492-1497.
[102]Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science,2004,305(5686): 1010-1013.
[103]Refai E,Dekki N,Yang SN,et al.Transthyretin constitutes a functional component in pancreatic beta-cell stimulus-secretion coupling[J].Proc Natl Acad Sci USA,2005,102:17020-17025.
[104]Dwulet FE,BensonMD.Characterization of transthyretin (prealbumin)vaiant associated amyloidotic polyneuiathy typeⅡ[J].J Clin Invest,1986,78(4): 880-886.
[105]Sousa MM,Berglund L,Saraiva MJ.Trnasthyretin in high density lipoproteins:
[106]Association with apolipoporteniA-Ⅰ [J].Joumal of Lipid Research,2000,41(1): 58-65.
[107]李钧敏,林启山,刘国诊,等.人血浆转甲状腺素蛋白的提纯及其对肝癌细胞生长的抑制作用[J].中国肿瘤生物治疗杂志1999,6(2)：97-101.